<DOC>
	<DOCNO>NCT00647933</DOCNO>
	<brief_summary>The objective study study pharmacokinetics , pharmacodynamics safety Org 36286 single subcutaneous administration healthy female .</brief_summary>
	<brief_title>An Open-label , Single Center Trial Assess Pharmacokinetics , Pharmacodynamics Safety Org 36286 ( P07004 )</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Mestranol</mesh_term>
	<mesh_term>Noracycline</mesh_term>
	<mesh_term>Lynestrenol</mesh_term>
	<criteria>Good physical mental health ; Body Mass Index 18 29 kg/m^2 ; Good venous accessibility ; Clinically relevant abnormal blood chemistry , hematology and/or urinalysis screening ; Hypertension ( sit diastolic blood pressure &gt; 90 mmHg and/or systolic blood pressure &gt; 150 mmHg ) ; Contraindications use oral contraceptive gonadotropin ; PAPsmear ( = III ) accord Papanicolaou classification ; History endocrine abnormality hyperprolactinaemia , polycystic ovary syndrome evidence ovarian dysfunction ; Primary ovarian failure ; Ovarian cyst enlarge ovary , relate polycystic ovarian disease ; Any ovarian and/or abdominal abnormality would interfere adequate ultrasound investigation ; Ovarian surgery ; Smoking 10 cigarette equivalent day ; History ( within 12 month ) alcohol drug abuse ; Blood donation ( &gt; 200 ml ) within 90 day prior screen ; Administration investigational drug within 90 day prior start Org 36286 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Females</keyword>
	<keyword>Corifollitropin alfa</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>